2024 KSoLA consensus on secondary dyslipidemia

Clinical Practice Guidelines Committee Korean Society of Lipid Atherosclerosis (KSoLA)

doi:10.3904/kjim.2024.156

2024 KSoLA consensus on secondary dyslipidemia

Clinical Practice Guidelines Committee Korean Society of Lipid Atherosclerosis (KSoLA)

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes of hypercholesterolemia and hypertriglyceridemia include an unhealthy diet, diseases and metabolic conditions affecting lipid levels, and therapeutic side effects. It is imperative to correct secondary causes prior to initiating conventional lipid-lowering therapy. Guideline-based lipid therapy can then be administered based on the subsequent lipid levels.

Original language	English
Pages (from-to)	717-790
Number of pages	74
Journal	Korean Journal of Internal Medicine
Volume	39
Issue number	5
DOIs	https://doi.org/10.3904/kjim.2024.156
Publication status	Published - Sept 2024

Bibliographical note

Publisher Copyright:
© 2024 The Korean Association of Internal Medicine.

Keywords

Diagnosis
Drug-related side effects and adverse reactions
Food
Lipoproteins
Metabolism

Access to Document

10.3904/kjim.2024.156

Cite this

@article{ebd8cbbaf02f4e6eaae8d0f56051977c,

title = "2024 KSoLA consensus on secondary dyslipidemia",

abstract = "Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes of hypercholesterolemia and hypertriglyceridemia include an unhealthy diet, diseases and metabolic conditions affecting lipid levels, and therapeutic side effects. It is imperative to correct secondary causes prior to initiating conventional lipid-lowering therapy. Guideline-based lipid therapy can then be administered based on the subsequent lipid levels.",

keywords = "Diagnosis, Drug-related side effects and adverse reactions, Food, Lipoproteins, Metabolism",

author = "\{Clinical Practice Guidelines Committee Korean Society of Lipid Atherosclerosis (KSoLA)\} and Hoyoun Won and Bae, \{Jae Hyun\} and Hyunjung Lim and Minji Kang and Minjoo Kim and Lee, \{Sang Hak\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Korean Association of Internal Medicine.",

year = "2024",

month = sep,

doi = "10.3904/kjim.2024.156",

language = "English",

volume = "39",

pages = "717--790",

journal = "Korean Journal of Internal Medicine",

issn = "1226-3303",

publisher = "Korean Association of Internal Medicine",

number = "5",

}

TY - JOUR

T1 - 2024 KSoLA consensus on secondary dyslipidemia

AU - Clinical Practice Guidelines Committee Korean Society of Lipid Atherosclerosis (KSoLA)

AU - Won, Hoyoun

AU - Bae, Jae Hyun

AU - Lim, Hyunjung

AU - Kang, Minji

AU - Kim, Minjoo

AU - Lee, Sang Hak

PY - 2024/9

Y1 - 2024/9

N2 - Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes of hypercholesterolemia and hypertriglyceridemia include an unhealthy diet, diseases and metabolic conditions affecting lipid levels, and therapeutic side effects. It is imperative to correct secondary causes prior to initiating conventional lipid-lowering therapy. Guideline-based lipid therapy can then be administered based on the subsequent lipid levels.

AB - Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes of hypercholesterolemia and hypertriglyceridemia include an unhealthy diet, diseases and metabolic conditions affecting lipid levels, and therapeutic side effects. It is imperative to correct secondary causes prior to initiating conventional lipid-lowering therapy. Guideline-based lipid therapy can then be administered based on the subsequent lipid levels.

KW - Diagnosis

KW - Drug-related side effects and adverse reactions

KW - Food

KW - Lipoproteins

KW - Metabolism

UR - https://www.scopus.com/pages/publications/85203170773

U2 - 10.3904/kjim.2024.156

DO - 10.3904/kjim.2024.156

M3 - Review article

AN - SCOPUS:85203170773

SN - 1226-3303

VL - 39

SP - 717

EP - 790

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

IS - 5

ER -

2024 KSoLA consensus on secondary dyslipidemia

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Chung-Ang University Hospital Researchers Report Recent Findings in Dyslipidemias (2024 KSoLA consensus on secondary dyslipidemia)

Cite this

2024 KSoLA consensus on secondary dyslipidemia

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Press/Media

Chung-Ang University Hospital Researchers Report Recent Findings in Dyslipidemias (2024 KSoLA consensus on secondary dyslipidemia)

Cite this